Cite
HARVARD Citation
Retz, M. et al. (2019). SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European journal of cancer. pp. 37-45. [Online].